Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR33532824

— · D

ff6d1404-d91d-58ca-a824-609c07fb513f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.460
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
  • PANCREAS_BETA_CELLS+0.330
  • HEDGEHOG_SIGNALING+0.300
  • TGF_BETA_SIGNALING+0.300
  • UV_RESPONSE_DN+0.300
  • MYC_TARGETS_V1+0.290
  • E2F_TARGETS+0.230
  • COAGULATION+0.190
  • OXIDATIVE_PHOSPHORYLATION+0.170

Top 10 suppressed

  • MITOTIC_SPINDLE-0.330
  • INTERFERON_GAMMA_RESPONSE-0.270
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
  • TNFA_SIGNALING_VIA_NFKB-0.230
  • INTERFERON_ALPHA_RESPONSE-0.210
  • IL6_JAK_STAT3_SIGNALING-0.200
  • PI3K_AKT_MTOR_SIGNALING-0.200
  • APICAL_SURFACE-0.190
  • ALLOGRAFT_REJECTION-0.170
  • PEROXISOME-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120020076.Her2HRpos
breast-umap@18
—C0.684
2SRR33532826
breast-umap@18
—D0.662
3TCGA-E2-A1IN-01A-11R-A13Q-07
breast-umap@18
—C0.662
4TCGA-66-2789-01A-01R-0980-07
lung-landscapes@6
—cohortSQ10.655
5MBCProject_0943_T1_RNA
breast-umap@18
—B0.644
6TCGA-AN-A04A-01A-21R-A034-07
breast-umap@18
—C0.628
7SRR493955
lung-landscapes@6
—cohortSC0.623
8SRR12202487
bladder-landscape@3
——0.616
965460
medullo-epn-umap@date-based
EPNSupratentorial EPN0.616
10SRR25617938
breast-umap@18
—B0.615

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.460Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.380Inavolisib— uncovered
PANCREAS_BETA_CELLS0.330Cobimetinib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
UV_RESPONSE_DN0.300Inavolisib— uncovered
MYC_TARGETS_V10.290Inavolisib— uncovered
E2F_TARGETS0.230Inavolisib— uncovered
COAGULATION0.190Binimetinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.170Remibrutinib— uncovered
PROTEIN_SECRETION0.160Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.130Idelalisib— uncovered
P53_PATHWAY0.120Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.110Remibrutinib— uncovered
SPERMATOGENESIS0.110Inavolisib— uncovered
ANDROGEN_RESPONSE0.100Inavolisib— uncovered
APICAL_JUNCTION0.090Inavolisib— uncovered
APOPTOSIS0.090Idelalisib— uncovered
KRAS_SIGNALING_UP0.090Inavolisib— uncovered
NOTCH_SIGNALING0.090Inavolisib— uncovered